Search results

Kära medlemmar i Nordic Network for Narratives in Medicine! Först och främst: Stort och varmt tack till er som medverkade i vårt nätverksmöte i Trondheim 13-14 juni och ett än varmare tack till briljanta organisatörer, ledda av Silje Haugen Warberg, Institutt for språk og litteratur, Norges teknisk-naturvitenskapelige universitet (NTNU)! Nyhetsbrevet läser ni i sin helhet i bifogad PDF, nedan i ko

https://www.medicinsk-humaniora.lu.se/sites/medicinsk-humaniora.lu.se/files/2025-05/Nyhetsbrev%20juni%202024%20(komplett).pdf - 2026-06-07

There are high demands on companies today to survive when competition is high and that also applies to companies that manufacture ethylene oxide. The raw material in the production of ethylene oxide is ethylene and oxygen where ethylene is the largest cost. To facilitate the reaction a catalyst, which increases the reaction rate, is used. The catalyst has a major influence on the efficiency and ec

Frågor och svar om felaktig demensdiagnos – Vetenskap och Hälsa Vetenskap och hälsa Populärvetenskapligt om medicinsk forskning i Skåne Teman Podd Tidskrift Prenumerera Om webbplatsen Kontakt Sök Sök Frågor och svar om felaktig demensdiagnos 2011-06-15 ⚠️ Den här artikeln är mer än 5 år gammal. Nya forskningsrön kan ha tillkommit. Vi har tidigare skrivit om nya forskningsrön från Lunds universitet

https://www.vetenskaphalsa.se/fragor-och-svar-om-felaktig-demensdiagnos/ - 2026-06-07

Protein ADP-ribosylation is a reversible post-translational modification that regulates important cellular functions. The identification of modified proteins has proven challenging and has mainly been achieved via enrichment methodologies. Random mutagenesis was used here to develop an engineered Af1521 ADP-ribose binding macro domain protein with 1000-fold increased affinity towards ADP-ribose. T

Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrat

We have characterized 2 distinct mechanisms through which infectious agents may promote platelet adhesion and thrombus formation in flowing blood, thus contributing to the progression of disease. In one case, the process initiates when the integrin alpha(IIb)beta(3) mediates platelet arrest onto immobilized bacterial constituents that have bound plasma fibrinogen. If blood contains antibodies agai

This review compares the methodology of published clinical studies investigating the extended-half-life (EHL) factor VIII (FVIII) products, rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®), BAY 94-9027 (damoctocog alfa pegol, Jivi®), BAX 855 (rurioctocog alfa pegol, Adynovate®) and N8-GP (turoctocog alfa pegol, Esperoct®) including the phase 2/3 studies, A-LONG (NCT01181128), PROTECT VIII (NCT01580

Lymphocytes from human peripheral blood were separated by Countercurrent distribution (CCD) in a charged aqueous two-phase system composed of Dextran T 500 and polyethylene glycol 6000. Maximal responses to the T-cell mitogens phytohemagglutinin and concanavalin A were detected in a part of the distribution corresponding to the area where the highest percentage of E rosetting cells were seen. Anti